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Abstract
Consolidation of fear memory requires neural changes to occur in the basolateral amygdala (BLA), including modulation of
histaminergic neurotransmission. We previously demonstrated that local blockade or activation of histamine H3 receptors in the
BLA impaired or ameliorated, respectively, retention of fear memory. The histamine H3 receptor is a G-protein-coupled receptor
(GPCR) displaying high constitutive activity that regulates histamine neurons in the brain. Proxyfan is a high-affinity histamine H3
receptor protean agonist exhibiting the full spectrum of pharmacological activities, from full agonist to full inverse agonist
depending on the competition between constitutively active and quiescent H3 receptors in a given tissue or brain region. Therefore,
protean agonists are powerful tools to investigate receptor conformation and may be useful in designing specific compounds
selective for the various receptor conformations. In the present study we examined the effect of post-training, systemic or intra-BLA
injections of proxyfan on contextual fear memory. Rats receiving intra-BLA, bilateral injections of 1.66 ng proxyfan immediately
after fear conditioning showed stronger memory for the context-footshock association, as demonstrated by longer freezing assessed
at retention performed 72 hr later compared to controls. Comparable results were obtained when doses as low as 0.04 mg/kg of
proxyfan were injected systemically. Hence, our results suggest that proxyfan behaves as an H3 receptor agonist with a low level of
constitutive activity of the H3 receptor in the rat BLA.
 2004 Elsevier Ltd. All rights reserved.
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activity1. Introduction
The therapeutic potential of H3 receptor antagonist/
inverse agonists for correcting cognitive deficits is
raising great interest. There is convincing evidence that
systemic administration of such compounds in experi-
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doi:10.1016/j.neuropharm.2004.09.009mental animals have procognitive effects in learning
paradigms such as the five-choice, serial reaction time
task (Ligneau et al., 1998), the object recognition test
(Giovannini et al., 1999), the two-choice place recogni-
tion test (Orsetti et al., 2001), the five-trial inhibitory
avoidance test (Fox et al., 2002a, 2003), the elevated-
plus maze task (Onodera et al., 1998) and in social
memory (Fox et al., 2003). However, when administered
locally, into restricted brain regions H3 ligands may
have other effects on the expression of some forms of
memory. For instance, post-training administrations of
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mide or clobenpropit into the basolateral amygdala
impair memory for aversive events (Passani et al., 2001),
whereas agonists such as R-a-methylhistamine improve
the expression of fear memory after contextual fear
conditioning (Cangioli et al., 2002). In the same learning
paradigm, post-training injections into the dorsal
hippocampus of R-a-methylhistamine improve memory
consolidation (Giovannini et al., 2003). Almost in-
variably, the behavioural effects of histaminergic com-
pounds have been studied following systemic or local
administration into small brain regions, which are
known to be crucial for the behavioural response under
study. Both approaches have advantages and caveats:
systemic treatments are clinically relevant, but hista-
minergic compounds are known to affect arousal,
anxiety, perception (Brown et al., 2001), and stress
(Westerink et al., 2002), therefore the mechanisms of
action remain unexplored. On the other hand, local
administrations of these compounds may reveal how the
histaminergic system affects cognitive processing by
modulating local neuronal circuitry, intracellular path-
ways and may explain potential unwanted, or side
effects of the molecules under investigation. In the
present study, we correlated the behavioural effects of
systemic and intra-basolateral amygdala (BLA), post-
training injections of proxyfan in the rat, on contextual
fear memory. Aversive training tests such as contextual
fear conditioning are used to assess emotional memory.
They implicate the association between a neutral cue
(the context, in this case) and a footshock. Re-exposure
to the same environment will induce a measurable
stereotyped behaviour. Furthermore, there is extensive
evidence that crucial neural changes mediating emo-
tional memory occur in the BLA (LeDoux, 2000). The
interest in proxyfan stems from the recent discovery that
the H3 receptor shows a high degree of agonist-
independent activity (Morisset et al., 2000), a phenom-
enon also referred to as constitutive activity, as
demonstrated both in vivo (Morisset et al., 2000) and
in vitro, in recombinant and native H3 receptors
(Rouleau et al., 2002). Several of the classical H3
antagonists, such as thioperamide and ciproxifan,
behave as potent inverse agonists, as they block the
intracellular pathways associated with active H3 recep-
tors in transfected cells (Morisset et al., 2000; Rouleau
et al., 2002). The high-affinity H3-receptor ligand
proxyfan (Ligneau et al., 2000; Morisset et al., 2001),
on the other hand, is a ‘‘protean’’ agonist, which
displays the full spectrum of pharmacological activities
from full agonism to full inverse agonism (Gbahou
et al., 2003). Little is known of the behavioural effects of
proxyfan. In a dipsogenia test in mice proxyfan behaves
as an antagonist/partial agonist (Fox et al., 2002b).
Furthermore, proxyfan modulates the sleep-wake cycle
in a different manner depending on the animal species(Gbahou et al., 2003), hence depending on the
conformation of the receptors and their constitutive
activity. The H3 receptor is apparently one of the most
highly constitutively active receptors so far detected,
hence we used proxyfan to study its functional
significance in a memory test that requires the activation
of the amygdala, one of the brain regions with the
highest density of H3 receptor mRNA and binding sites
in the rat (Pillot et al., 2002).
2. Materials and Methods
2.1. Animals
Male albino Wistar rats (average body weight 290 g)
were used in all experiments. Rats were individually
housed in a room with a natural light–dark cycle and
constant temperature (20G 1 C), and had free access
to food and water throughout the experiments. Animals
used in this study were cared for in accordance with the
guidelines of the European Community recommenda-
tions (86/606/CEE) and were approved by the Animal
Care Committee of the Universita` di Firenze.
2.2. Behavioural experiments
2.2.1. Apparatus
Contextual fear conditioning was induced in a basic
Skinner box module (Modular Operant Cage, Coul-
bourn Instruments Inc., PA, USA) as in previous
experiments (Cangioli et al., 2002; Passani et al.,
2001). Box dimensions were 29! 31! 26 cm. The top
and the two opposite sides were made of aluminium
panels, the other two sides of transparent plastic and the
floor of stainless steel rods connected to a shock delivery
apparatus (Grid Floor Shocker, model E13-08, Coul-
bourn Instruments Inc. PA, USA). The number of the
electric shocks and the inter-shock interval duration was
predetermined by a stimulus programming device
(Scatola di comando Arco 2340, Ugo Basile, Italy).
The apparatus was placed in an acoustically insulated
room kept at a constant temperature of 20G 1 C.
Illumination inside the room was 60 lux.
2.2.2. Contextual fear conditioning procedure
The rat was gently taken manually from the home
cage, placed in a bucket and carried from the housing
to the soundproof room, and then placed in the
conditioning apparatus (contextual cue). The rat was left
undisturbed for 3 min. and subsequently seven 1-s, 1-mA
electric footshocks were administered at 30-s intervals.
The rat was removed 2 min after the end of the stimula-
tion, therefore spending a total time of 8 min inside
the conditioning apparatus. The same conditioning
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i.p. or intra-BLA injections of proxyfan.
2.2.3. Conditioned freezing measurements
Freezing is one of the behavioural manifestations of
conditional fear in rats, and consists of the complete
absence of voluntary movements. Freezing duration was
measured 72 hr after conditioning. To measure freezing,
the animals were again placed inside the conditioning
apparatus in the soundproof room and left for 6 min,
during which they did not receive electrical stimulation.
After that time, they were brought back to the home
cage. Rat’s behaviour was recorded by means of a closed
circuit television system by an experimenter unaware of
the animal’s treatment. Freezing time was measured
with a stop watch. All behavioural tests were performed
between 10:00 and 12:00 hr to avoid a Kamin effect
(Kamin, 1957).
2.2.4. Systemic administrations of proxyfan
Rats were injected intraperitoneally immediately
post-acquisition with a constant volume (0.4 ml) of
physiological solution in which proxyfan had been
dissolved at the appropriate concentrations. Doses were
extrapolated from those used in mice (Morisset et al.,
2000). Control groups received 0.4-ml injections of
physiological solution. After the injection the rats were
returned to their home cages. During the following 3
days before testing, rats displayed a normal behaviour
that did not differ from that of animals that received
intra BLA injections of saline.
2.2.5. Surgery and intra-amygdala drug administration
Rats were anaesthetized immediately after the train-
ing session with ketamine (100 mg/kg i.p.), and bilateral
injections took place within the following 10 min.
Animals were restrained in the stereotaxic apparatus
and secured by means of two ear pins and a maxillary
bar. After incision of the scalp, 2-mm holes were drilled
in the skull at the appropriate sites, and care was taken
not to open the dura mater. Insertion of the injection
needle was performed according to the coordinates:
APZ2.8 mm, LZ4.9, DVZ3.8 from bregma (Pax-
inos and Watson, 1998). Different concentrations of
proxyfan were dissolved in physiological saline and
injected bilaterally into the BLA. The tip of the needle
was placed 8.7 mm ventral to bregma. The injection
needle had an outside diameter of 0.3 mm, and was
connected with a short piece of polyethylene tubing to
a Hamilton syringe fixed to an electrode holder.
Solutions (0.5 ml per side) were injected over a 1–2 min
period and the needle was left in place for another min
before withdrawing it. Control groups received bilateral
injections of saline. The surgical incision was then closed
with metal stitches. After surgery, the rats were returned
to their home cages. During the following 3 days beforetesting, the animals displayed a normal behaviour that
did not differ from that of controls.
2.2.6. Exploratory and locomotor activity
The intraperitoneal injections of proxyfan did not
cause any modification in animals’ behaviour during the
3 days between training and testing. Intra-BLA injected
animals recovered from surgery and general anaesthesia
within 24 hr, and in the following 48 hr did not show
any abnormal behaviour. Furthermore, immediately
after the retention test, all animals were placed on
a round table of 1.5 m diameter and their behaviour was
observed for 3 min. Data from rats showing abnormal
locomotor and exploratory activities, grooming, yawn-
ing and rearing were not included.
2.3. Histology
At the end of the experiments, rats were deeply
anaesthetized with ketamine, the brains were removed
and stored in 10% formalin for 10 days. Brain sections
were cut with a freezing microtome and Nissl-stained to
verify injection sites. Only animals with correct place-
ment of the injection needles within the boundaries of
the BLA were used for data analysis.
2.4. Data analysis
For each session, data were expressed as seconds
spent freezing within the 6 min of testing. One-way
ANOVA and the Neuman–Keuls post hoc test were
used. For all statistical tests, P!0:05 was considered
significant.
3. Results
Fig. 1 shows the effect of increasing doses of proxyfan
on the expression of fear memory. Proxyfan was
administered i.p. immediately after training, and the
animals were tested for memory retention 72 hr after
training. Analysis of variance and Neuman–Keuls post
hoc analysis for freezing behaviour showed a significant
treatment effect (F4;34Z4:614; P!0:01). Rats that re-
ceived either 0.04 mg/kg (nZ8) or 0.2 mg/kg (nZ9)
proxyfan spent significantly more time freezing than
saline-injected controls (nZ10) when tested for contex-
tual fear retention. There was no significant difference
between animals that received 0.02 mg/kg proxyfan
(nZ6), 2 mg/kg (nZ6) and controls (nZ10). As the
amygdala participates in the elaboration of highly
emotional, aversive memories (see Maren, 2001 for
a review), we examined the effect of post-training
bilateral injections of proxyfan into the BLA on
contextual fear memory retention. Proxyfan was diluted
in saline to permit the bilateral injection of constant
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revealed a significant treatment effect (F2;27Z3:831;
P!0:05), and Neuman–Keuls post hoc analysis showed
that rats receiving bilateral, intra BLA injections of 1.66
ng proxyfan (which corresponds to 10 mM; nZ9) spent
more time freezing than saline injected controls
(nZ11; P!0:05), because these rats showed a stronger
response for the footshock-context association (Fig. 2).
There was no significant difference, however, between
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Fig. 1. Effect of post-training systemic administrations of proxyfan on
contextual fear conditioning. Proxyfan was freshly prepared and
diluted in sterile saline. Control rats received i.p. injections of saline.
Freezing was measured 72 hr after training over a 6 min period during
re-testing. Each bar represents the mean valueG S.E.M. of (n) rats.
Doses are expressed as mg/kg. *P! 0.05 vs. controls (Neuman–Keuls
test).
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Fig. 2. Effects of post-training bilateral injection of proxyfan into the
BLA on contextual fear conditioning. Immediately after training rats
were injected with proxyfan under general anaesthesia. Seventy-two
hours after training, freezing was measured during the 6-min period of
testing. Each bar represents the mean valueGS.E.M. of (n) rats.
**P!0.05 vs. control (Neuman–Keuls test).animals treated with 0.166 ng (1 mM) proxyfan and
controls.
4. Discussion
The present study provides the first evidence of the
enhancing effects of the ‘‘protean’’ H3 receptor agonist
proxyfan, on consolidation of fear memories. The H3
receptor is one of the few GPCRs to have been described
as having a physiological role in its constitutively active
form controlling histaminergic neurons activity in vivo
(Morisset et al., 2000). Recently, evidence was provided
that the 5-HT2C receptor as well is constitutively active
in vivo, where it exerts an inhibitory control on
nigrostriatal and mesolimbic DA neuronal pathways
(Deurwaerdere et al., 2004). GPCRs are allosteric
proteins that adopt inactive (R) and active (R*)
conformations in equilibrium. R* is promoted by
agonists or occurs spontaneously, leading to constitutive
activity of the receptor. Conversely, inverse agonists
promote R and decrease constitutive activity. Classical
antagonists of the H3 receptors such as thioperamide
and ciproxifan block constitutive activity, and therefore
were demonstrated to act as inverse agonists. The
existence of another pharmacological entity, referred
to as ‘‘protean’’ agonists, was assumed on theoretical
grounds (Kenakin, 1995). It was predicted from the
existence of constitutive activity that the same ligand
could act either as an agonist or an inverse agonist at the
same GPCR. Proxyfan behaves as a protean agonist, as
it shows a spectrum of activities that range from full
agonist to full inverse agonist at distinct functional
responses within different animal species. In the learning
paradigm used in the present study, contextual fear
conditioning, proxyfan mimicked the memory-enhanc-
ing effect of H3 receptor agonists administered locally
either in the amygdala (Cangioli et al., 2002), or in the
hippocampus (Giovannini et al., 2003) in contextual fear
conditioning. Accordingly, rats that received systemic
administrations of proxyfan showed a stronger response
to the footshock-context association, as they spent more
time freezing in the retention test. Full agonism of
proxyfan was observed also in the cat, where it
significantly increased deep slow-wave sleep, without
affecting wakefulness, whereas in the mouse proxyfan
behaved as a full inverse agonist (Gbahou et al., 2003),
mimicking the arousal effect of the antagonist/inverse
agonist ciproxifan (Parmentier et al., 2002), and as
a partial agonist in the dipsogenia model (Fox et al.,
2002b). Presumably, the agonist effect of proxyfan in
our model implies that in the rat amygdala H3 receptors
are predominantly in a quiescent state and constitutive
activity has a low efficacy. In rats, though, enzyme
immunoassay experiments have shown that proxyfan
decreased the levels of the histamine metabolite
250 E. Baldi et al. / Neuropharmacology 48 (2005) 246–251t-MeHA, in the cortex, hence behaving as an inverse
agonist, which presumes a high efficacy of the constitu-
tively active H3 receptor (Gbahou et al., 2003). This is in
agreement with the hypothesis that competition between
the active and inactive forms of the receptor may be
responsible for the heterogeneity of pharmacological
responses in different brain regions (Gbahou et al.,
2003). But the pharmacology of H3 receptors is very
complex, and when evaluating behavioural responses,
other factors such as polymorphism (both in humans
and rodents) with a differential distribution of splice
variants in the CNS, and potential coupling to different
g-protein signaling pathways (see Passani and Blandina,
2004 for a review) should be kept in mind. This
heterogeneity may contribute to the various effects of
histaminergic ligands when tested in disparate brain
regions and across animal species to alter the entire
range of behavioural responses. Nonetheless, in our
study proxyfan affected the expression of fear memory
in a comparable manner when administered either
systemically or into the BLA, a result that corroborates
the theory that amygdala constitutes one of the core
elements of a circuit that regulates emotional responses.
As for other compounds that affect learning and
memory (McGaugh, 1989), systemic administration of
proxyfan induced an inverted U-shaped, dose–response
curve. An analogous phenomenon could not be shown
with localized injections into the amygdala, because
higher doses than the ones we used do not guarantee
that proxyfan diffusion remains confined to the BLA. It
is worth mentioning that both systemic and local
injections of proxyfan were carried out post-training,
which is a protocol that excludes any influence of the
treatment on acquisition and on other processes that
indirectly may affect learning (McGaugh and Izquierdo,
2000). The pharmacological treatments interfered with
memory consolidation as they were performed immedi-
ately after training, whereas the retention test was
carried out 72 hr later; therefore, the observed memory
enhancement is to be considered the expression of
improved long term, contextual fear memory. Compar-
ison between freezing time of rats that received intra-
BLA injections of saline and those that received systemic
saline injections confirm the hypothesis that post-trial
ketamine anaesthesia and surgical procedures that were
performed to inject proxyfan in the BLA do not
influence negatively avoidance responses by interfering
with some late stages of memory consolidation. These
findings validate previously reported observations that
unoperated and ketamine-anaesthetized rats that re-
ceived intra-amygdala saline injections exhibited similar
freezing responses to context and acoustic conditioned
stimuli (Sacchetti et al., 1999). In conclusion, the
complexity of the pharmacological responses induced
by protean agonists is such that their therapeutic
applicability may be disputable at this moment, as theirefficacy may vary among brain regions and pathology
addressed. However, protean agonists may help dis-
criminate between different receptor conformations in
various neuroanatomical structures and contribute to
the understanding of the functional significance of
constitutive activity.
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